As of 2019, Ian C. Read owned 1.6 million shares of Pfizer, valued at about $46.5 million. This significant holding showed his commitment to Pfizer's growth and demonstrated alignment with shareholder interests. Throughout his tenure, he maintained a substantial stake...

As of 2019, Ian C. Read owned 1.6 million shares of Pfizer, valued at about $46.5 million. This significant holding showed his commitment to Pfizer's growth and demonstrated alignment with shareholder interests. Throughout his tenure, he maintained a substantial stake in the company, reflecting his confidence in its future. His wealth from holdings fluctuated based on Pfizer's market performance, emphasizing his focus on long-term value. Read’s ownership peaked when he had over $46 million in stock, underscoring the value he placed on performance-based success. It was a strategic decision that mirrored his approach to executive compensation, where he also focused on performance metrics, ensuring that executive profits correlate with company success. Overall, Read’s stock holdings were a testament to his dedication to Pfizer’s growth and success.